Interim Results for Gastric Cancer Treatment With Ramucirumab Plus Pembrolizumab
January 21st 2017Ian Chau, MD, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.
Watch
Esophageal Cancer Outcomes Improved by PET-Guided Treatment
January 20th 2017Pathologic complete response (pCR) rates were improved by switching neoadjuvant chemotherapy regimens based on PET imaging after induction chemotherapy in patients with esophageal and gastroesophageal junction (GEJ) cancers, according to findings from the phase II CALGB 80803 study.
Read More
Study Results Show Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer
January 20th 2017According to findings from the phase III ONO-4538-12 trial, treatment with nivolumab (Opdivo) reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction (GEJ) cancer following second or later-line chemotherapy.
Read More
The Impact of Age, Comorbidity on Postoperative Outcomes in Esophageal and Gastric Cancer
January 20th 2017Christophe Mariette, MD, PhD, surgical oncologist and professor of surgery, University Hospital of Lille in France, discusses a nationwide study investigating the impact of age and comorbidities on postoperative mortality after esophageal and gastric cancer surgery.
Watch
Encouraging Findings With Ribociclib in HR+ Breast Cancer
December 21st 2016Harold J. Burstein, MD, PhD, institute physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CDK 4/6 inhibitor ribociclib and its clinical activity in patients with hormone receptor (HR)-positive breast cancer.
Watch
Ribociclib Demonstrates Significant Benefit in Advanced Breast Cancer
December 17th 2016Patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib (LEE011) combined with letrozole, a subgroup analysis of the randomized MONALEESA-2 trial showed.
Read More
Prolonged PFS From Addition of Ipilimumab to Nivolumab in Advanced NSCLC
December 16th 2016Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.
Read More
Response to Durvalumab Increased With High PD-L1 Expression in Pretreated NSCLC
December 16th 2016Durvalumab treatment in the second-line setting or beyond demonstrated clinical benefit and led to durable responses in heavily pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Read More
France Takes Step Toward Standardizing PD-L1 Immunohistochemistry Testing
December 13th 2016Determining the PD-L1 status of a patient’s tumor has become increasingly important for informing the clinical decision whether to offer certain immunotherapeutic agents, making standardization of the tests and antibodies used to determine the PD-L1 status necessary to provide accurate and consistent results.
Read More
Carboplatin Does Not Produce Greater Response Over Docetaxel in BRCA1 Methylated or Silenced TNBC
December 13th 2016BRCA1 methylation or silencing does not predict for a better response to carboplatin over docetaxel in women with advanced triple-negative or BRCA1/2 breast cancer, according to results from a pre-planned biological analysis of the phase III TNT trial.
Read More
Continuous Low-Dose Ribociclib Active in Advanced Breast Cancer Causes Less Neutropenia
December 13th 2016Continuous low-dose ribociclib shows preliminary activity, and has an acceptable safety profile as an alternative to intermittent ribociclib dosing when combined with fulvestrant in the treatment of postmenopausal women with hormone receptor-positive, <em>HER2</em>-negative advanced breast cancer.
Read More
Pembrolizumab Continues to Show Durable Benefit in Heavily Pretreated TNBC
December 12th 2016Pembrolizumab (Keytruda) continued to show a consistent durable benefit with an additional year of follow-up for heavily pretreated patients with recurrent PD-L1-positive metastatic triple-negative breast cancer.
Read More
Computer Program Achieves High Concordance in Tumor Board Test
December 12th 2016The artificial intelligence computer program Watson for Oncology (WFO) achieved a high degree of concordance with tumor board recommendations in a double-blinded validation study in Bengaluru, India, according to results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
Read More
Genomic Analysis of CALGB 40601 for HER2-Positive Breast Cancer
December 12th 2016Maki Tanioka, MD, PhD, a postdoctoral research associate at UNC Lineberger Comprehensive Cancer Center, discusses an integrated analysis of multidimensional genomic data on the phase III CALGB 40601 (Alliance) study, which explored neoadjuvant weekly paclitaxel and trastuzumab (Herceptin) with or without lapatinib for patients with HER2-positive breast cancer,
Watch
Lead neoMONARCH Researcher Provides Insight on Abemaciclib Potential in HR-Positive Breast Cancer
December 11th 2016Recent promising findings with the neoadjuvant combination of the CDK4/6 inhibitor abemaciclib with anastrozole could lead to a novel therapeutic option for patients with hormone receptor (HR)–positive, HER2-negative early breast cancer.
Read More
Combination of Veliparib and Chemotherapy in BRCA-Positive Breast Cancer
December 10th 2016Hyo Sook Han, MD, medical oncologist, Moffitt Cancer Center, discusses results of the phase II BROCADE trial, which evaluated the combination of the PARP inhibitor veliparib with carboplatin/paclitaxel in patients with <em>BRCA</em>-positive breast cancer.
Watch
Takeaways From TransATAC Trial on Comparing Prognostic Signatures
December 10th 2016William J. Gradishar, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, discusses the takeaways from the TransATAC trial, which was a comprehensive comparison of prognostic signatures in breast cancer.
Watch
Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib
December 10th 2016Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses what sets abemaciclib apart from other CDK 4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.
Watch
AI Therapy May Put Breast Cancer Survivors at Risk For Cardiovascular Disease
December 10th 2016Aromatase inhibitor (AI) therapy may pose a risk of cardiovascular disease to postmenopausal women with early-stage breast cancer, raising the possibility of a long-term complication in an era of growing survivorship when patients are treated with estrogen-targeting drugs for years.
Read More
Scalp Cooling Devices Safe and Effective to Use for Patients Receiving Chemotherapy
December 10th 2016Findings from the first prospective, randomized clinical trial to evaluate modern scalp-cooling demonstrate that the system is safe and effective in reducing hair loss in women being treated with chemotherapy for their breast cancer, especially for those on taxane-based regimens.
Read More
Neoadjuvant Estrogen Fails to Significantly Improve Response Rates in High-Risk Breast Cancer
December 10th 2016An attempt to strengthen neoadjuvant treatment of patients with locally advanced HR-positive and HER2-positive breast cancer by adding estrogen deprivation therapy to a standard regimen failed to significantly improve response rates.
Read More
Loperamide/Budesonide Combo Prevents Neratinib-Associated Diarrhea for Breast Cancer Patients
December 10th 2016Prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade ≥3 diarrhea associated with neratinib to 15% compared with 39.9% observed in the ExteNET trial. The rate of all-grade diarrhea was 65% with the prophylactic regimen versus 95.4% in ExteNET, according to findings from the phase II CONTROL trial.
Read More